BTBP(SH:600161) 智通财经网·2025-12-04 09:17Core Viewpoint - TianTan Biological (600161.SH) announced that its subsidiary, Guizhou Biological Pharmaceutical Co., Ltd., has completed Phase III clinical trials for "Prothrombin Complex Concentrate" and received the clinical trial summary report [1] Group 1: Clinical Trial Results - The clinical trial results indicate that the Prothrombin Complex Concentrate significantly enhances coagulation factor levels II/VII/IX/X in patients with Hemophilia B [1] - The treatment improves coagulation function and alleviates bleeding symptoms and signs in patients with Hemophilia B, demonstrating good efficacy [1] Group 2: Safety Analysis - Safety analysis results show that the drug has a good safety profile during clinical application for patients with Hemophilia B [1]